Drugs / edratide
edratide
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00203151 | Jul 2005 → Feb 2007 | systemic lupus erythematosus | Teva Branded Pharmaceutical Products R&D, Inc. | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2007-09-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Results Teva Provides Update On Edratide For Systemic Lupus Erythematosus tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) announced today that the Company's synthetic peptide, edratide (TV-4710), did not meet its primary endpoint in the PRELUDE trial, a Phase 2 clinical trial in patients with systemic lupus erythematosus (SLE). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2007-09-19 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Provides Update On Edratide For Systemic Lupus Erythematosus tevapharm.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | edratide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00203151 ↗ |
| Known as | Edratida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107743 ↗ |
| Known as | hCDR1 | “Safety and efficacy of hCDR1 (Edratide) in patients with active systemic lupus erythematosus: results of phase II study.” PMID 26301100 ↗ Aug 2015 |
| Known as | TV-4710 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107743 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL2107743 ↗ |
| Route | Subcutaneous | “Placebo or Edratide was administered subcutaneously weekly at doses of 0.5, 1.0 or 2.5 mg.” PMID 26301100 ↗ Aug 2015 |